just saw the alert from Fido .. :) now we know why we

New Post Public Reply Private Reply Replies (3) Message Board
4kids AlanC #44701
686
just saw the alert from Fido ..

now we know why we saw the last two week's hiked volume and relentless compression

nicely done Innovation ..


Innovation Pharmaceuticals Signs Drug Supply Contract with Evonik to Bulk Produce Commercial-Grade Brilacidin


My fellow IPIX shareholders,

As we await the unblinding of the Prurisol clinical trial, I am very pleased to inform everyone that we have taken the next step in development of our Brilacidin franchise by contracting the specialty chemical experts at Evonik. As measured by our interaction with pharmaceutical companies here and abroad, we believe that there is momentum building behind Brilacidin, particularly on the strength of our latest results in the Phase 2 trial for oral mucositis in head and neck cancer patients receiving chemoradiation. The conversations with companies, as well as with radiation oncologists and others close to patients, reinforce our conviction that the market for oral mucositis is many times our market capitalization. We’re thrilled to be working with Evonik to move Brilacidin forward as expeditiously as possible.

Best wishes,
Innovation Pharmaceuticals

Innovation Pharmaceuticals Signs Drug Supply Contract with Evonik to Bulk Produce Commercial-Grade Brilacidin

BEVERLY, MA – April 23, 2018 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has signed a drug supply contract with Evonik Corporation, a world leader in specialty chemicals, for the bulk production of commercial-grade Brilacidin to prepare for, as well as expedite, its continued clinical development.

Brilacidin is a versatile compound exhibiting broad therapeutic potential in a new chemical class called defensin-mimetics. The drug candidate, with unique and robust immunomodulatory, anti-inflammatory, and antibacterial properties, has successfully been tested in clinical trials in oral mucositis, ulcerative proctitis/ulcerative proctosigmoiditis, and serious skin infections.

“We are delighted to have been selected by Innovation Pharmaceuticals to scale up and industrialize the production of Brilacidin, a phase 3 drug compound advancing in multiple development programs under Fast Track designations and look forward to contribute to the success of this franchise,” said Dr. Andreas Meudt, Vice President, Product Line Exclusive Synthesis at Evonik’s Health Care Business Line.

Securing a commercial-grade drug supply of Brilacidin with a leading Contract Development and Manufacturing Organization (CDMO), such as Evonik, is an important and necessary step that will enable Innovation Pharmaceuticals to more rapidly advance the Brilacidin Franchise, toward getting much-needed treatments to patients.

“We are pleased to have Evonik’s expertise applied to the CMC efforts integral to moving our Brilacidin programs toward the finish line,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “We anticipate this drug substance, to be manufactured to the high standards and philosophy of Quality by Design (QbD), will provide for our long-term needs across multiple anchored clinical indications in the Brilacidin Franchise.”

About Evonik Corporation

Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2017, the enterprise generated sales of €14.4 billion and an operating profit (adjusted EBITDA) of €2.36 billion. More information is available at: www.evonik.com.

Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
www.ipharminc.com/email-alerts/

About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious disease, and dermatologic diseases. Brilacidin, a versatile compound with broad therapeutic potential, is in a new chemical class called defensin-mimetics. A Phase 2 trial of Brilacidin-OM, an oral rinse for the prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer, met its primary and secondary endpoints, including reducing the incidence of SOM. Positive results were also observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis. A Phase 2b trial of Brilacidin showed a single intravenous dose of the drug delivered comparable outcomes to a seven-day dosing regimen of the FDA-approved blockbuster daptomycin in treating Acute Bacterial Skin and Skin Structure Infections. Kevetrin is a novel anti-cancer drug shown to modulate p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations, and has successfully completed a Phase 2 trial in ovarian cancer. Prurisol, an oral psoriasis drug candidate acting through immune modulation and PRINS reduction, completed a Phase 2b trial with topline results expected in 2Q2018. More information is available on the Company website at www.IPharmInc.com.

Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning projected timelines for the initiation and completion of clinical trials, our future drug development plans, other statements regarding future product developments, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause the Company’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Company’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that the Company’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in the Company’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.


Copyright © 2018 Innovation Pharmaceuticals, All rights reserved.
You requested to receive email alerts about Innovation Pharmaceuticals at our website http://www.ipharminc.com/
Our mailing address is:
Innovation Pharmaceuticals
100 Cummings Center, Suite 151-B
Beverly, MA 01915


Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEPAS AURA Signals a Sharper Design Bet for Future Cars

Updated Category News Views 145

A porcelain-smooth concept car is not a balance sheet, but it can tell you where a young automotive brand intends to spend its attention. LEPAS unveiled AURA in October at its first Global Elegant Lifestyle Week, presenting it as the brand's first global concept car and a fresh expression of its Leopard Aesthetics design language. That matters because AURA is plainly not...

Continue Reading
Valley Family Health Breach Notice Raises Hard Questions

Updated Category News Views 41

Seven months is a long time for sensitive patient data to sit inside an unresolved security story. Valley Family Health Care, Inc. says it suffered a network disruption on or about March 13, 2026, investigated with outside cybersecurity specialists, and ultimately determined that an unauthorized actor accessed and acquired certain files. The formal notification process...

Continue Reading
Chemours Legal Succession Gets a Long Transition Runway

Updated Category News Views 46

A corporate-law handoff rarely sets pulses racing, but this one deserves a proper look. Chemours is replacing its long-serving general counsel while keeping the departing executive in the building for four additional months. That is not flashy, and thank goodness for that. In a global chemicals company, legal leadership touches regulation, compliance, governance,...

Continue Reading
Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 91

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
Visual Cipher Bench Exposes AI Agents' Hidden Rule Gap

Updated Category News Views 95

Forty little black-and-white puzzles just threw a bucket of cold water on the autonomous-agent sales pitch. Einsia AI’s Navers Lab says its new Visual Cipher Bench found that the best result among eight frontier models was only 26.7%, with no tested configuration clearing 30%. That is not a minor blemish. It is a reminder that a model can sound clever, use tools, and...

Continue Reading
SAGA's Radar Assays Tighten the Trapper North Case

Updated Category News Views 125

Rock that keeps showing up where the model says it should is the sort of boring news a junior miner desperately needs. SAGA Metals has put out fresh assay results from Radar’s Trapper North area, and the useful part is not merely a loud grade in one hole. It is the apparent persistence of thick titanium-vanadium-iron oxide mineralization across tighter-spaced drilling....

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 117

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading
BKV Energy's $400,000 Loyalty Bet Has a Real Point Behind It

Updated Category News Views 73

Retail power customers rarely send thank-you notes; they switch plans, complain about bills, or quietly vanish. That is why BKV Energy putting more than $400,000 into its third annual ElectroShare payout deserves a harder look than the usual feel-good loyalty announcement. A Retention Expense With Some Teeth The payout has climbed quickly: roughly $113,000 in the first...

Continue Reading
MERSCO’s Holiday Push Tests Backyard Play Demand in 2026

Updated Category News Views 22

A trampoline sale is not exactly a macroeconomic bellwether, but it does expose a useful little corner of holiday spending: parents buying big, awkward, discretionary stuff that has to earn its space in the yard. MERSCO is joining Amazon’s Black Friday and Cyber Monday window from November 19 through November 30, 2026, with discounts reaching 38% on selected products....

Continue Reading
Elijah Craig Uses AI Toasts to Sell a Warmer Pour

Updated Category News Views 38

A Speech Prompt With a Bourbon Label Few things expose holiday nerves faster than a raised glass and a room waiting for somebody to say something memorable. Elijah Craig has decided that awkward little moment is marketing territory, rolling out its Digital Perfect Pour, Perfect Toast Generator for mobile and desktop users ahead of the holiday season. The tool asks for a...

Continue Reading
/section>

Top 5 Most Recently Viewed Articles

Unveiling Groundbreaking Research on Cenobamate at AES 2025

Updated Category News Views 163

Exciting New Developments in Epilepsy Treatment SK Life Science, Inc., a leading player in central nervous system (CNS) disorder treatments and a subsidiary of SK Biopharmaceuticals Co., Ltd., is ready to unveil ten posters featuring new research on cenobamate at the upcoming American Epilepsy Society (AES) Annual Meeting. This prestigious event will take place in...

Continue Reading
Teck Resources Unveils Strong First Quarter Earnings for 2025

Updated Category News Views 384

Teck Resources Limited Reports Impressive First Quarter Results Teck Resources Limited (NYSE: TECK, TSX: TECK.A, TSX: TECK.B) has announced its unaudited financial results for the first quarter of 2025, showcasing significant improvements over previous years. This marks a period of enhanced profitability driven by favorable market conditions. Financial Performance...

Continue Reading
Understanding Your Rights in the Symbotic Class Action

Updated Category News Views 155

Taking Action: Your Rights as an Investor in Symbotic Inc. Investors of Symbotic Inc. should be aware of a class action lawsuit initiated on their behalf. The law firm Kirby McInerney LLP is advocating for those who acquired Symbotic securities during the noted class period. This comes as a crucial reminder for shareholders to stay informed and consider their rights in...

Continue Reading
Scott Kelly Joins Worthington Steel Board, Boosting Strategy

Updated Category News Views 431

Scott Kelly Named to Worthington Steel Board Worthington Steel, Inc. (NYSE:WS), a prominent player in the metals processing industry, has officially welcomed Scott Kelly to its board of directors. This strategic appointment comes at a significant time as the company navigates its market challenges, including a recent 10% dip in stock price. Despite this, Worthington...

Continue Reading
Treasury Securities Agreements: A New Era for Primary Dealers

Updated Category News Views 232

Understanding the Latest Developments in Treasury Securities In a significant move to fortify the issuance and market making in Treasury securities, the Government Debt Management, on behalf of the Treasury, has signed crucial agreements with primary dealers. This initiative aims to ensure the Treasury’s uninterrupted access to financing while enhancing price formation...

Continue Reading